Posted by Michael Wonder on 24 Feb 2020
ICER and Aetion partner to develop real-world evidence for value assessment of treatments
24 February 2020 - ICER adopts Aetion’s Real-World Evidence Platform — advancing standards for the use of transparent, replicable real-world evidence in health technology assessment.
Today, the Institute for Clinical and Economic Review (ICER) announced it has selected Aetion as a preferred partner and platform to generate decision-grade real-world evidence (RWE).
The announcement comes on the heels of ICER’s commitment to expand use of RWE to complement other sources of information used in its value assessments, and it furthers ICER’s mission of catalysing a movement toward fair pricing, fair access, and future innovation across the entire U.S. health system.
